Plain-English translation of NCT06123884 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing a new medication called BAT1308 that helps your immune system fight cervical cancer. You would receive this medication as an infusion (IV drip) combined with standard chemotherapy drugs, and possibly another anti-cancer medication called bevacizumab. The research team wants to see if adding this treatment improves survival and how well it works compared to chemotherapy alone.
Cervical cancer that has spread or come back after treatment is very difficult to treat, and current options don't work well enough for many women. This trial is testing whether this new immune-boosting medication could help more patients live longer and control their cancer better.
You likely qualify if…
You likely don't qualify if…
If you join this study, you would receive the new medication BAT1308 as an IV infusion once every three weeks, combined with standard chemotherapy and possibly another medication. The study has two phases: first, a smaller group (20–50 women) will test safety and early results; if that goes well, a larger group (476 women) will be randomly assigned to either receive the new treatment or a placebo combined with standard chemotherapy. You would have regular clinic visits for infusions, blood tests, and scans to monitor how well the treatment is working. The study will track your health and survival over time.
AI-generated summary from trial data · Jun 24, 2026 · Not medical advice
China